HK104292A - Kit for treating osteoporosis - Google Patents

Kit for treating osteoporosis

Info

Publication number
HK104292A
HK104292A HK1042/92A HK104292A HK104292A HK 104292 A HK104292 A HK 104292A HK 1042/92 A HK1042/92 A HK 1042/92A HK 104292 A HK104292 A HK 104292A HK 104292 A HK104292 A HK 104292A
Authority
HK
Hong Kong
Prior art keywords
kit
treating osteoporosis
treatment
amethodfortreating
cyclesthe
Prior art date
Application number
HK1042/92A
Other languages
English (en)
Inventor
Lawrence Flora
Benjamin Franklin Floyd
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24983007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK104292(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of HK104292A publication Critical patent/HK104292A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Removal Of Specific Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
HK1042/92A 1985-06-06 1992-12-24 Kit for treating osteoporosis HK104292A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/741,976 US4761406A (en) 1985-06-06 1985-06-06 Regimen for treating osteoporosis

Publications (1)

Publication Number Publication Date
HK104292A true HK104292A (en) 1992-12-31

Family

ID=24983007

Family Applications (1)

Application Number Title Priority Date Filing Date
HK1042/92A HK104292A (en) 1985-06-06 1992-12-24 Kit for treating osteoporosis

Country Status (13)

Country Link
US (1) US4761406A (fi)
EP (1) EP0210728B2 (fi)
JP (1) JP2509185B2 (fi)
AT (1) ATE128356T1 (fi)
AU (1) AU603766B2 (fi)
CA (2) CA1338376E (fi)
DE (1) DE3650403T3 (fi)
DK (1) DK174584B1 (fi)
FI (1) FI862407A (fi)
GB (1) GB2177001B (fi)
HK (1) HK104292A (fi)
PH (1) PH23686A (fi)
ZA (1) ZA864149B (fi)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
DE3770787D1 (en) * 1986-11-21 1991-07-18 Ciba Geigy Ag Aromatisch substituierte azacyclo-alkylalkandiphosphonsaeuren.
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
US5190930A (en) * 1987-12-11 1993-03-02 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
US5110807A (en) * 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
US7452359B1 (en) * 1988-06-13 2008-11-18 Warsaw Orthopedic, Inc. Apparatus for inserting spinal implants
AU5185790A (en) * 1989-02-16 1990-09-05 University Of Georgia Research Foundation, Inc., The Treatment of tibial dyschondroplasia
US5316770A (en) * 1989-02-16 1994-05-31 University Of Georgia Research Foundation, Inc. Vitamin D derivative feed compositions and methods of use
US5366736A (en) * 1989-02-16 1994-11-22 University Of Georgia Research Foundation, Inc. Vitamin D derivative feed compositions and methods of use
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5204334A (en) * 1990-10-18 1993-04-20 Ciba-Geigy Corporation Benzoheterocyclylalkylaminoalkanediphosphonic acids, compositions thereof, and use thereof in the treatment of calcium metabolism disorders
ATE119777T1 (de) 1991-02-26 1995-04-15 Procter & Gamble Pharma Behandlungsmethoden für osteoporose.
DK0531253T3 (da) * 1991-08-27 1997-01-27 Ciba Geigy Ag N-substituerede aminomethandiphosphonsyrer
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
JP4481368B2 (ja) * 1992-06-30 2010-06-16 味の素株式会社 骨粗鬆症の治療用のためのホスホネート類の用途
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
EP0809502A4 (en) * 1995-02-17 2001-12-05 Merck & Co Inc PROCESS FOR REDUCING THE RISK OF BONE FRACTURES OTHER THAN VERTEBRAL FRACTURES
EP0831756A1 (en) 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
WO2000023594A1 (en) 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2002533115A (ja) * 1998-12-31 2002-10-08 ザ ジェネラル ホスピタル コーポレーション Ｐｔｈ機能的ドメイン結合体ペプチド、それらの誘導体、および新規係留リガンド−レセプター分子
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
EP1222208B1 (en) 1999-09-29 2008-10-29 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6833357B2 (en) * 2000-06-20 2004-12-21 The Trustees Of The University Of Pennsylvania Compositions and methods for modulating muscle cell and tissue contractility
NZ523086A (en) * 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
US20050147602A1 (en) * 2000-10-19 2005-07-07 Maine Medical Center Research Institute Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
AU2002339843B2 (en) * 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US20030119771A1 (en) * 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
US20080057059A1 (en) * 2001-11-09 2008-03-06 Novo Nordisk Healthcare A/G Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
KR20120065435A (ko) 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
FR2841472B1 (fr) 2002-06-28 2006-02-24 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives
US20050031610A1 (en) * 2002-07-19 2005-02-10 Tae-Wan Kim CD44-related fragments, compositions and methods
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
BE1015150A3 (nl) * 2002-10-21 2004-10-05 Sonitron Nv Verbeterde transducent
BR0309691A (pt) * 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
WO2004067021A1 (en) * 2003-01-24 2004-08-12 Gardella Thomas J Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
FR2853549B1 (fr) 2003-04-11 2007-11-09 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
EP1673336B1 (en) 2003-08-21 2014-06-04 Merck Canada Inc. Cathepsin cysteine protease inhibitors
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
KR20080083068A (ko) 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1855674B1 (en) 2005-03-02 2014-07-16 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin k
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
EP1888037A2 (en) * 2005-05-10 2008-02-20 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
RU2437565C2 (ru) * 2005-06-02 2011-12-27 Ю. Эс. Боракс Инк. Композиция кормового продукта для профилактики или лечения остеохондроза (варианты), способ профилактики или лечения остеохондроза
US20080293677A1 (en) * 2005-06-06 2008-11-27 Brookler Kenneth H Use of Alternating Amine and Non-Amine Bisphosphonate Combinations For Treating Osteoporosis
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
US7781418B2 (en) 2006-12-14 2010-08-24 Isis Innovation Ltd. Composition for treating bone disorders
AU2008282805B2 (en) 2007-08-01 2014-05-01 Chugai Pharmaceutical Co., Ltd. Screening methods using G-protein coupled receptors and related compositions
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
RU2604809C2 (ru) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
CN102372773B (zh) * 2010-08-11 2013-06-05 中国科学院生物物理研究所 人膀胱癌肿瘤标志物及其抗体和应用
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2716297B1 (en) * 2011-03-11 2017-09-27 Tokyo University of Science Foundation D-glu-fniii14 polypeptide for use in treating cancer
PL2731591T3 (pl) 2011-07-13 2021-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomy zawierające bisfosfonian i środek amfipatyczny w wyniku ko-enkapsulacji
FR3005419B1 (fr) 2013-05-13 2015-09-04 Agronomique Inst Nat Rech Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux
CN105593230B (zh) 2013-10-08 2018-07-06 默沙东公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
FR3066919B1 (fr) 2017-06-06 2019-08-02 Institut National De La Recherche Agronomique (Inra) Composition de phycocyanine pour son utilisation pour inhiber la resorption osseuse.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IT1195993B (it) * 1984-01-12 1988-11-03 Gentili Ist Spa Forme farmaceutiche a base di difosfonati
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.

Also Published As

Publication number Publication date
EP0210728B1 (en) 1995-09-27
EP0210728B2 (en) 2005-08-17
ZA864149B (en) 1988-11-30
DE3650403D1 (de) 1995-11-02
EP0210728A2 (en) 1987-02-04
JPS6248627A (ja) 1987-03-03
PH23686A (en) 1989-09-27
CA1338376E (en) 1996-06-18
FI862407A (fi) 1986-12-07
DK268486D0 (da) 1986-06-06
US4761406A (en) 1988-08-02
ATE128356T1 (de) 1995-10-15
GB8613585D0 (en) 1986-07-09
DE3650403T2 (de) 1996-03-28
AU603766B2 (en) 1990-11-29
AU5836986A (en) 1986-12-11
DK174584B1 (da) 2003-07-07
DK268486A (da) 1986-12-07
DE3650403T3 (de) 2006-06-14
EP0210728A3 (en) 1989-06-07
CA1282702C (en) 1991-04-09
GB2177001A (en) 1987-01-14
JP2509185B2 (ja) 1996-06-19
GB2177001B (en) 1989-12-28
FI862407A0 (fi) 1986-06-05

Similar Documents

Publication Publication Date Title
GB2177001B (en) Kit for treating osteoporosis
BG46024A1 (en) Method and device for treatment of bone patology
GEP20084347B (en) New derivatives of diphosphonic acid, method for their preparation and medicamentous form containing them
ZA976562B (en) Isobutylgaba and its derivatives for the treatment of pain.
EP0203580A3 (en) Gamma-ifn as an agent for the inhibition (hindering) of the decay process of bones
GB8605264D0 (en) Treating bone fractures
GB2190523B (en) Cryptographic based electronic lock system and method of operation
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
IE871567L (en) Method for treating depression
GB2198158B (en) Steam treatment of an article and apparatus therefor
BG40176A1 (en) Method for chirurgical treatment of mandible fractures
PL253486A2 (en) Method of treating effluents from hospitals for contagious diseases in particular tuberculosis
SU1572581A1 (ru) Cпocoб лeчehия диaфизaphыx пepeлomob kocteй пpeдплeчья
CS522286A1 (en) Method of waste hydrogen chloride treatment
NZ331846A (en) Method for preparing a medicament using olanzapine for treating insomnia
UA29236A (uk) Спосіб лікування пізніх гестозів
UA10000A (uk) Спосіб лікування гострої недостатності тканинного дихання
PL262644A1 (en) Method of treatment of refinery wastes
SU1568986A1 (ru) Cпocoб xиpуpгичeckoгo лeчehия hижheй пpo-и makpoгhatии
CS278589A1 (en) Method of waste hydrogen chloride treatment
SU1572584A1 (ru) Уctpoйctbo для лeчehия пepeлomob kocteй taзa
UA13880A (uk) Спосіб профілактики післяопераційhих ускладhеhь
PH24147A (en) Method of treating functional hallux limitus
BG41280A1 (en) Device for generating cyclic code combinations and precompensating of data

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060603